Agilent to Acquire AI Pathology Software Maker Proscia for $240M
A sits 59% above its 52-week low of $108.35.
Summary
Agilent is buying privately held Proscia for $240 million in cash, with up to $30 million more tied to performance targets. Proscia's software digitizes pathology slides for AI analysis, and the deal expands Agilent's push into AI-enabled diagnostics. The target generated over $18 million in revenue in the past year, implying a rich multiple but a strategic fit given the companies' distribution partnership since 2022. Closing is expected early in fiscal 2027. This follows Agilent's strong Q3 and recent EU certification for its PD-L1 companion diagnostic, reinforcing its diagnostics growth strategy.
At the time of this announcement, A was trading at $172.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $48.3B. The 52-week trading range was $108.35 to $177.05. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.